Volume 24, Number 1Prostate CancerAdvanced Tools for Risk Stratification in Prostate Cancer: A Contemporary Review of Commercially Available Molecular Genomic and Digital Histopathology TestsRyan J. HuttenTraditional risk stratification in localized prostate cancer provides broad treatment guidance but lacks the precision necessary for individualized care. Commercially available biomarkers, including Decipher (Veracyte), Prolaris (Myriad Genetics, Inc), Genomic Prostate Score (mdxhealth), and ArteraAI, have recently demonstrated improved prognostic and predictive capabilities. These tools can assist clinical decision-making in key scenarios, including active surveillance, intensification of treatment with definitive radiation, and postoperative management. This review synthesizes the current evidence supporting these biomarkers, emphasizing their validation, clinical utility, and potential to refine prostate cancer management. Understanding the development and limitations of these biomarkers is crucial for their appropriate integration into patient care.precision medicineProstatic neoplasmsBiomarkers